Ajanta Pharma Ltd
Ajanta Pharma Ltd (AJANTPHARM) last traded at ₹3,563, a market capitalisation of ₹44,524 crore, on a P/E of 39.3. Over the past 52 weeks the stock has ranged between ₹2,330 and ₹3,797. Ajanta Pharma Ltd last reported results for the quarter ended Jun 2026, with sales of ₹1,626 crore and net profit of ₹334 crore. Figures are as of 25 Aug 2026 and are not real time.
Ajanta Pharma Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Ajanta Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹1,626 cr, up 24.8% from ₹1,303 cr a year earlier. Net profit was ₹334 cr, up 31.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,187 | 1,146 | 1,170 | 1,303 | 1,354 | 1,375 | 1,422 | 1,626 |
| Expenses | 875 | 825 | 873 | 951 | 1,026 | 993 | 1,088 | 1,202 |
| Operating profit | 311 | 321 | 297 | 351 | 328 | 382 | 333 | 424 |
| OPM % | 26% | 28% | 25% | 27% | 24% | 28% | 23% | 26% |
| Other income | 19 | 30 | 18 | 26 | 59 | 25 | 61 | 71 |
| Interest | 6 | 8 | 6 | 5 | 3 | 5 | 2 | 3 |
| Depreciation | 34 | 36 | 40 | 41 | 43 | 44 | 45 | 44 |
| Profit before tax | 290 | 307 | 269 | 331 | 341 | 359 | 347 | 447 |
| Tax % | 25% | 24% | 16% | 23% | 24% | 24% | 23% | 25% |
| Net profit | 216 | 233 | 225 | 255 | 260 | 274 | 267 | 334 |
| EPS (₹) | 17.33 | 18.64 | 18.03 | 20.44 | 20.83 | 21.91 | 21.35 | 26.75 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Ajanta Pharma Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 2,890 | 3,341 | 3,743 | 4,209 | 4,648 | 5,453 | 5,776 |
| Operating profit | 1,001 | 933 | 808 | 1,172 | 1,269 | 1,500 | 1,467 |
| OPM % | 35% | 28% | 22% | 28% | 27% | 28% | 25% |
| Net profit | 654 | 713 | 588 | 816 | 920 | 1,056 | 1,135 |
| EPS (₹) | 50.38 | 55.63 | 45.89 | 63.70 | 73.68 | 84.52 | 90.84 |
TTM is the trailing twelve months to the most recent quarter.
Ajanta Pharma Ltd growth and returns
- 10 Years
- 12%
- 5 Years
- 14%
- 3 Years
- 13%
- TTM
- 20%
- 10 Years
- 10%
- 5 Years
- 12%
- 3 Years
- 24%
- TTM
- 22%
- 10 Years
- 11%
- 5 Years
- 19%
- 3 Years
- 28%
- 1 Year
- 37%
- 10 Years
- 23%
- 5 Years
- 23%
- 3 Years
- 25%
- Last Year
- 27%
Ajanta Pharma Ltd shareholding pattern
Promoters held 63.49% at Jun 2026, down from 66.26% at Jun 2025. FIIs 7.68% and DIIs 21.80%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 66.26% | 66.26% | 66.26% | 66.26% | 66.25% | 66.25% | 66.25% | 63.49% |
| FIIs | 9.11% | 9.26% | 8.86% | 8.86% | 8.53% | 7.97% | 8.26% | 7.68% |
| DIIs | 17.09% | 17.02% | 17.48% | 17.50% | 17.90% | 18.58% | 18.36% | 21.80% |
| Government | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.00% |
| Public | 7.51% | 7.45% | 7.38% | 7.38% | 7.32% | 7.20% | 7.14% | 7.03% |
| No. of shareholders | 64,315 | 66,896 | 70,827 | 68,882 | 67,785 | 65,409 | 67,955 | 65,296 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Ajanta Pharma Ltd corporate filings
- The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 19, 2026 for Ravi Agrawal, trustee ....Insider Trading / SASTlow impact
Cruxal's analysis: Ajanta Pharma Limited has disclosed that promoter Ravi Agrawal (Trustee of Ravi Agrawal…
Read the full analysis - The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 14, 2026 for Ravi Agrawal, trustee ....Insider Trading / SASTmedium impact
Cruxal's analysis: Ajanta Pharma Limited has disclosed that promoter Ravi Agrawal (Trustee of Ravi Agrawal…
Read the full analysis - Pls find enclosed Intimation w.r.t participation in Investor ConferenceCompany Updatelow impact
Cruxal's analysis: Ajanta Pharma has issued a formal intimation regarding its participation in an investor…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Ajanta Pharma Ltd
Cruxal reads every Ajanta Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.